Empowered Patient Podcast

Palak Shah is a physical therapist and Co-Founder of Luna who is attacking the problem of providing physical therapy to the growing population of patients with the need to receive in-person care by a physical therapist.

Palak explains, "What is super different about Luna is that we're not a home health agency. We're bringing out physical therapy to patient homes for all our patients in 19 states and 32 metro markets today. Having about 1,200 therapists on the platform now throughout the country, bringing technology and high-quality care from the therapists, is Luna's superpower. The vision here is what we're trying to bring with technology and these amazing quality therapists is to reimagine the physical therapy experience."

"All of Luna's therapists are moonlighting with Luna, more than 95% and hence the name Luna. So they are working at outpatient clinics today that are in our community, but also have this amazing opportunity to participate with an organization like Luna that allows them supplemental income."

@GetLunaCare #COVID19 #HomePhysicalTherapy #HospitalatHome #PhysicalTherapist #PT #PhysicalTherapy #Recovery #Rehab #RehabatHome #Rehabilitation #RehabTherapy #Treatment

GetLuna.com

Listen to the podcast here

Palak Shah is a physical therapist and Co-Founder of Luna who is attacking the problem of providing physical therapy to the growing population of patients with the need to receive in-person care by a physical therapist.

Palak explains, "What is super different about Luna is that we're not a home health agency. We're bringing out physical therapy to patient homes for all our patients in 19 states and 32 metro markets today. Having about 1,200 therapists on the platform now throughout the country, bringing technology and high-quality care from the therapists, is Luna's superpower. The vision here is what we're trying to bring with technology and these amazing quality therapists is to reimagine the physical therapy experience."

"All of Luna's therapists are moonlighting with Luna, more than 95% and hence the name Luna. So they are working at outpatient clinics today that are in our community, but also have this amazing opportunity to participate with an organization like Luna that allows them supplemental income."

@GetLunaCare #COVID19 #HomePhysicalTherapy #HospitalatHome #PhysicalTherapist #PT #PhysicalTherapy #Recovery #Rehab #RehabatHome #Rehabilitation #RehabTherapy #Treatment

GetLuna.com

Download the transcript here

Dr. Daniel Schneeberger is the CEO of Anebulo Pharmaceuticals and is determined to find an antidote to acute cannabinoid intoxication, a growing problem for people of all ages as well as emergency rooms around the country.

Daniel says, "THC acts mostly in the brain, it crosses the blood-brain barrier and binds to the CB1 receptor, and it activates that CB1 receptor. Our drug also goes to the brain and binds to the same receptor, much more tightly, up to 100x more tightly, and blocks it so that THC has no chance to act on that receptor anymore. One of the most important properties of our drug, too, is rapid absorption with oral dosing. So we feel very good about the drug candidate."

"These drugs, CB1 antagonists, were originally developed for weight loss in the treatment of diabetes back around 2007, 2008. They were never approved by the FDA because with chronic dosing, there was an increased frequency of depression, it was 9%, it was 5% with placebo. Back then, the FDA was very concerned that chronic dosing in such a large patient population might potentially be unsafe. For our drug, it's a one-time dose, and those mood effects only showed up with chronic dosing."

@AnebuloP #CannabisIntoxication #AcuteCannabisIntoxication #Cannabinoids #SyntheticCannabinoids #SubstanceAbuseDisorders

Anebulo Pharmaceuticals

Listen to the podcast here

Dr. Daniel Schneeberger is the CEO of Anebulo Pharmaceuticals and is determined to find an antidote to acute cannabinoid intoxication, a growing problem for people of all ages as well as emergency rooms around the country.

Daniel says, "THC acts mostly in the brain, it crosses the blood-brain barrier and binds to the CB1 receptor, and it activates that CB1 receptor. Our drug also goes to the brain and binds to the same receptor, much more tightly, up to 100x more tightly, and blocks it so that THC has no chance to act on that receptor anymore. One of the most important properties of our drug, too, is rapid absorption with oral dosing. So we feel very good about the drug candidate."

"These drugs, CB1 antagonists, were originally developed for weight loss in the treatment of diabetes back around 2007, 2008. They were never approved by the FDA because with chronic dosing, there was an increased frequency of depression, it was 9%, it was 5% with placebo. Back then, the FDA was very concerned that chronic dosing in such a large patient population might potentially be unsafe. For our drug, it's a one-time dose, and those mood effects only showed up with chronic dosing."

@AnebuloP #CannabisIntoxication #AcuteCannabisIntoxication #Cannabinoids #SyntheticCannabinoids #SubstanceAbuseDisorders

Anebulo Pharmaceuticals

Download the transcript here

Gary Rotman and Bruce Barnet are Co-Founders of SiMPL Technology, a company designing and selling simple tech products for seniors and their caregivers. With a particular focus on people with cognitive challenges and discomfort with digital technology, SiMPL is bringing solutions to the market that solve such challenges as medication adherence and media access.

Gary is an inventor and explains, "So, I've been in the timepiece industry for most of my career, over 35 years, so one of the products I developed was a talking clock, and you can set the alarm by voice. In the meantime, like many other people, my father was diagnosed with dementia back in 2010, Alzheimer's dementia, and I woke up one day with this aha moment to put personalized messages in the clock. So, when my mother isn't home, and my dad forgets his meds and doesn't want to end up back in the hospital, this talking clock would announce in my mother's voice, "Honey, take your pills now.".

Bruce says, "So the things that we think are easy, are not easy for a person that's been afflicted with dementia. Even to the point of when a person grew up as I did, I'm 70 years old, grew up seeing an analog clock with a long hand and a short hand. Today, everything is digital. A person with dementia, who's remembering what it was like to be 14 or 20 years old, doesn't understand how to connect the dots on digital, so it needs to be LED if it's going to be in that type of form at all. You really have to think about what it is that they consider normal at a certain age."

#SiMPL #SiMPLTechnology #GaryRotman #BruceBarnet #Rosie2.0 #DementiaCareProgram #Alzheimers #Dementia

SMPLTEC.com

Listen to the podcast here

Gary Rotman and Bruce Barnet are Co-Founders of SiMPL Technology, a company designing and selling simple tech products for seniors and their caregivers. With a particular focus on people with cognitive challenges and discomfort with digital technology, SiMPL is bringing solutions to the market that solve such challenges as medication adherence and media access.

Gary is an inventor and explains, "So, I've been in the timepiece industry for most of my career, over 35 years, so one of the products I developed was a talking clock, and you can set the alarm by voice. In the meantime, like many other people, my father was diagnosed with dementia back in 2010, Alzheimer's dementia, and I woke up one day with this aha moment to put personalized messages in the clock. So, when my mother isn't home, and my dad forgets his meds and doesn't want to end up back in the hospital, this talking clock would announce in my mother's voice, "Honey, take your pills now.".

Bruce says, "So the things that we think are easy, are not easy for a person that's been afflicted with dementia. Even to the point of when a person grew up as I did, I'm 70 years old, grew up seeing an analog clock with a long hand and a short hand. Today, everything is digital. A person with dementia, who's remembering what it was like to be 14 or 20 years old, doesn't understand how to connect the dots on digital, so it needs to be LED if it's going to be in that type of form at all. You really have to think about what it is that they consider normal at a certain age."

#SiMPL #SiMPLTechnology #GaryRotman #BruceBarnet #Rosie2.0 #DementiaCareProgram #Alzheimers #Dementia

SMPLTEC.com

Download the transcript here

Dr. Nick West is the Chief Medical Officer and DVP Global Medical Affairs for Vascular at Abbott. With the launch of the Ultreon software 1.0, Abbott is bringing a new level of analysis to their Optical Coherence Tomography intracoronary imaging tool.

Nick explains, "And the idea of this software package is, on top of this best-in-class in terms of resolution imaging technology to help physicians, the Ultreon software augments physician decision-making to effectively enable them to do a better job, but more easily."

"Optical Coherence Tomography already existed. A very powerful tool, as I said. A very high degree of precision and accuracy in measurement. However, one of the issues with OCT is that, as well as understanding how to actually physically use the catheter, which is reasonably straightforward, it's very similar to other devices that interventional cardiologists use, but they then have to learn to interpret the images you get out. So acquiring the pictures is relatively straightforward, but then how do you interpret these detailed pictures?"

"You still need to know how to use the catheter, but the Ultreon 1.0 software uses machine learning algorithms. That's artificial intelligence, if you like, where we've taught the software over hundreds and hundreds of different OCT pictures. We taught it - what is calcification? What is that hardened narrowing? And also, where is what we call the external elastic lamina?"

@AbbottCardio #OCT #OpticalCoherenceTomography #angiograms #UltreonSoftware #medicalimaging #coronaryhealth

Abbott.com

Listen to the podcast here

Dr. Nick West is the Chief Medical Officer and DVP Global Medical Affairs for Vascular at Abbott. With the launch of the Ultreon software 1.0, Abbott is bringing a new level of analysis to their Optical Coherence Tomography intracoronary imaging tool.

Nick explains, "And the idea of this software package is, on top of this best-in-class in terms of resolution imaging technology to help physicians, the Ultreon software augments physician decision-making to effectively enable them to do a better job, but more easily."

"Optical Coherence Tomography already existed. A very powerful tool, as I said. A very high degree of precision and accuracy in measurement. However, one of the issues with OCT is that, as well as understanding how to actually physically use the catheter, which is reasonably straightforward, it's very similar to other devices that interventional cardiologists use, but they then have to learn to interpret the images you get out. So acquiring the pictures is relatively straightforward, but then how do you interpret these detailed pictures?"

"You still need to know how to use the catheter, but the Ultreon 1.0 software uses machine learning algorithms. That's artificial intelligence, if you like, where we've taught the software over hundreds and hundreds of different OCT pictures. We taught it - what is calcification? What is that hardened narrowing? And also, where is what we call the external elastic lamina?"

@AbbottCardio #OCT #OpticalCoherenceTomography #angiograms #UltreonSoftware #medicalimaging #Angioplasty #coronaryhealth

Abbott.com

Download the transcript here

Dr. Mike Dudley is President and CEO of QpexBiopharma and seeing drug-resistant infections occurring inside the hospital as well as outside the hospital. Qpex is developing IV and oral drugs that are designed to overcome resistance mechanisms in bacteria that render penicillin-like drugs inactive.

Mike explains, "We deliver our drug in combination with existing antibiotics that have already been proven safe and effective as first-line therapies but have lost their usefulness due to resistant bacteria. And we want to be able to give them via vein for the sickest patients who can't take oral drugs. But also we want to be delivering them using an oral formulation in our product so they can be taken orally."

"We call the IV product OMNIvance, which provides that coverage for very, very sick patients. And then an oral product, which we call ORAvance that can be then delivered orally, and it can be useful for stepping down hospitalized patients or even treating infections in the community setting where you don't have to go to the hospital and can remain at home."

@QpexBio #QpexBio #AMR #AntimicrobialResistance #InfectiousDisease #SanDiego

QpexBio.com

Listen to the podcast here

Dr. Mike Dudley is President and CEO of QpexBiopharma and seeing drug-resistant infections occurring inside the hospital as well as outside the hospital. Qpex is developing IV and oral drugs that are designed to overcome resistance mechanisms in bacteria that render penicillin-like drugs inactive.

Mike explains, "We deliver our drug in combination with existing antibiotics that have already been proven safe and effective as first-line therapies but have lost their usefulness due to resistant bacteria. And we want to be able to give them via vein for the sickest patients who can't take oral drugs. But also we want to be delivering them using an oral formulation in our product so they can be taken orally."

"We call the IV product OMNIvance, which provides that coverage for very, very sick patients. And then an oral product, which we call ORAvance that can be then delivered orally, and it can be useful for stepping down hospitalized patients or even treating infections in the community setting where you don't have to go to the hospital and can remain at home."

@QpexBio #QpexBio #AMR #AntimicrobialResistance #InfectiousDisease #SanDiego

QpexBio.com

Download the transcript here